^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AUTO3

i
Other names: AUTO3, AUTO 3, CD19/22 CAR T cells, anti-CD19/22 CART cell therapy
Associations
Company:
Autolus
Drug class:
CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
11ms
ALEXANDER: CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=73, Completed, Autolus Limited | Active, not recruiting --> Completed | Trial completion date: Nov 2024 --> Dec 2023 | Trial primary completion date: Nov 2024 --> Dec 2023
Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
|
Keytruda (pembrolizumab) • cyclophosphamide • AUTO3
over1year
Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma. (PubMed, Blood)
Overall, AUTO3 +/- pembrolizumab for r/r LBCL was safe, lending itself to outpatient administration, and delivered durable remissions in 54.4% of complete responders, associated with robust CAR-T expansion. Neither dual-targeting CAR-T nor pembrolizumab prevented relapse in a significant proportion of patients, and future developments include next-generation-AUTO3, engineered for superior expansion/persistence in vivo, and selection of CAR binders active at low antigen densities.
Journal • CAR T-Cell Therapy
|
PD-1 (Programmed cell death 1) • CD22 (CD22 Molecule)
|
Keytruda (pembrolizumab) • AUTO3
2years
Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL (ASH 2022)
Building on these properties, we developed AUTO1/22 an autologous CAR T cell product co-transduced with two different lentiviral vectors encoding our existing CD19 CAR and a novel CD22CAR designed to recognise targets with low antigen density...Following fludarabine/cyclophosphamide lymphodepletion, patients received 1x106 /kg CAR+ T cells...Six of 12 patients had relapsed post allogeneic SCT, 6 had received prior Blinatumomab/Inotuzumab and 4 had relapsed after prior Tisagenlecleucel...Cytokine release syndrome (CRS) occurred in 11/12 patients (grade 1 n=5, grade 2 n=6) requiring Tocilizumab in 5 cases, but severe (≥ grade 3) CRS was not seen and no patients required ICU admission for CRS... Our data show that dual CD19/22 targeting CAR T cells generated by co-transduction show a favorable safety profile, with robust expansion/persistence and early efficacy in a heavily pre-treated cohort. To date with we have not observed antigen negative relapse. This contrasts to an incidence of 5/6 CD19 negative relapses in the 12 responders treated with single CD19 targeting CAR T cells (AUTO1) in an earlier cohort and suggests dual targeting may be effective in preventing antigen escape.
CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule) • CD34 (CD34 molecule)
|
cyclophosphamide • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Actemra IV (tocilizumab) • Aucatzyl (obecabtagene autoleucel) • AUTO1/22 • AUTO2 • AUTO3
almost3years
ALEXANDER: CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=73, Active, not recruiting, Autolus Limited | N=171 --> 73 | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Enrollment change • CAR T-Cell Therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
|
Keytruda (pembrolizumab) • AUTO3
3years
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. (PubMed, Nat Med)
Relapses were probably due to limited long-term AUTO3 persistence. Strategies to improve CAR T cell persistence are needed to fully realize the potential of dual targeting CAR T cell therapy in B-ALL.
Clinical • P1 data • Clinical Trial,Phase I • Journal • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
AUTO3
over3years
ALEXANDER: CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=171, Recruiting, Autolus Limited | Trial completion date: Mar 2022 --> Sep 2024 | Trial primary completion date: Mar 2022 --> Sep 2024
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • BCL6 rearrangement • BCL2 rearrangement
|
Keytruda (pembrolizumab) • AUTO3
over3years
ALEXANDER: CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
P1/2, N=171, Recruiting, Autolus Limited | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • BCL6 rearrangement • BCL2 rearrangement
|
Keytruda (pembrolizumab) • AUTO3
4years
[VIRTUAL] Phase 1 Alexander Study of AUTO3, the First CD19/22 Dual Targeting CAR T Cell Therapy, with Pembrolizumab in Patients with Relapsed/Refractory (r/r) DLBCL (ASH 2020)
AUTO3 at RP2D dose range of > 50 x 106 CAR T cells with D-1 pembrolizumab induces durable complete remissions. None of the patients in CR experienced severe CRS or neurotoxicities of any grade. Outpatient cohort is currently enrolling.
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD19 (CD19 Molecule)
|
Keytruda (pembrolizumab) • AUTO3
over4years
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
CD19 (CD19 Molecule)
|
Keytruda (pembrolizumab) • AUTO3
over4years
AMELIA: CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
P1/2, N=23, Completed, Autolus Limited | Active, not recruiting --> Completed | Trial completion date: Dec 2021 --> May 2020 | Trial primary completion date: Dec 2021 --> May 2020
Clinical • Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
CD19 expression
|
AUTO3
over4years
[VIRTUAL] PHASE 1 ALEXANDER STUDY OF AUTO3 THE FIRST BICISTRONIC CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING CD19 AND CD22 WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (EHA 2020)
Lymphodepletion was done with fludarabine and cyclophosphamide. Two out of 3 patients achieved CR at 450 x 106 cells on pem regimen B. Additional patients and longer follow up, as well as biomarkers, will be presented. Conclusion AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TNFRSF4 (TNF Receptor Superfamily Member 4)
|
Keytruda (pembrolizumab) • fludarabine IV • AUTO3
over4years
[VIRTUAL] Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL. (ASCO 2020)
AUTO3 at > 50 x 106 CAR T cells with pembrolizumab induces CRs without severe CRS or neurotoxicities of any grade. Research Funding: Autolus Therapeutics
Clinical • P1 data • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TNFRSF4 (TNF Receptor Superfamily Member 4)
|
Keytruda (pembrolizumab) • AUTO3
5years
Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study (ASH 2019)
In this study, we are evaluating the safety and efficacy of AUTO3, a CAR T cell therapy designed to target CD19 and CD22 simultaneously followed by 3 doses of anti-PD1 monoclonal antibody pembrolizumab (Pem) treatment...All patients received lymphodepletion with 30 mg/m2/day fludarabine and 300 mg/m2/day cyclophosphamide for 3 days prior to AUTO3 infusion...Only one case (9%) of neurotoxicity was noted which was grade 3 and treated with steroids and tocilizumab... AUTO3, a novel bicistronic anti CD19/CD22 CAR T therapy, has a manageable safety profile in combination with Pem. Notable is the lack of severe CRS (0%). The efficacy data with 2/4 patients achieving CR at dose 150 x 10e6 cells is promising.
Clinical • P1/2 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • fludarabine IV • Actemra IV (tocilizumab) • AUTO3